Nano-Porous Alumina Membranes for Enhanced Hemodialysis Performance

用于增强血液透析性能的纳米多孔氧化铝膜

基本信息

批准号：
7052580
负责人：
WILLIAM H VAN GEERTRUYDEN
金额：
$ 19.4万
依托单位：
EMV TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-20 至 2007-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7052580
关键词：
aluminum oxide artificial membranes bioengineering /biomedical engineering biomaterial development /preparation chronic renal failure hemodialysis membrane permeability molecular weight polymers scanning electron microscopy serum albumin technology /technique development thermostability

项目摘要

DESCRIPTION (provided by applicant): End stage renal disease (ESRD) has consistently been a major medical problem worldwide. By the year 2010, the number of ESRD patients in the United States is projected to be 661,330 with an increase of 78% compared to 372,407 in the year 2000. The total annual cost of Medicare for ESRD patients in the United States is projected to be $28.3 billion by the year 2010, an increase of 99% compared to $14.2 billion in the year 2000. Current hemodialysis membranes used in kidney dialysis have difficulty in removing uremic toxins from the blood. Nano-porous alumina tubes have gained significant interest in drug delivery and gas separation technologies and, as of yet, their use as membranes for hemodialysis has not been researched. The objective of this project is to create nano-porous alumina tubes with average pore sizes of 5 nm using a process of anodizing aluminum tubes under controlled conditions. There are several advantages of alumina membranes over the membranes currently used including: high porosity and uniform pore size, high hydraulic conductivity (water permeability), uniform pore distribution, excellent pore structure, high resistance to chemical and thermal degradation, and superior mechanical properties. The pore size and porosity will be measured by Scanning Electron Microscopy (SEM), while membrane permeability will be tested by a custom designed setup. Finally, a prototype mini-module hemodialyzer will be constructed and the clearance of a wide spectrum of molecular weight solutes (from low to high molecular weight solutes) will be evaluated. This research will address the needs of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), specifically its Division of Kidney, Urologic, and Hematologic Diseases. The NIDDK is seeking "the development of new dialysis membranes to diminish the duration of dialysis treatments." When commercialized, the new membranes will deliver a higher average dose to dialysis patients and increase their quality of life.

描述（由申请人提供）：终末期肾病（ESRD）一直是世界范围内的一个主要医学问题。到 2010 年，美国 ESRD 患者人数预计将达到 661,330 人，比 2000 年的 372,407 人增加 78%。美国 ESRD 患者每年的医疗保险总费用预计为到2010年将达到283亿美元，比2000年的142亿美元增长99%。目前用于肾透析的血液透析膜难以从血液中去除尿毒症毒素。纳米多孔氧化铝管在药物输送和气体分离技术方面引起了人们的极大兴趣，但迄今为止，它们作为血液透析膜的用途尚未得到研究。该项目的目标是使用在受控条件下对铝管进行阳极氧化的工艺来制造平均孔径为 5 nm 的纳米多孔氧化铝管。与目前使用的膜相比，氧化铝膜有几个优点，包括：高孔隙率和均匀的孔径、高导水率（透水性）、均匀的孔分布、优异的孔结构、高抗化学和热降解性以及优异的机械性能。孔径和孔隙率将通过扫描电子显微镜（SEM）测量，而膜渗透性将通过定制设计的装置进行测试。最后，将构建微型模块血液透析器原型，并评估各种分子量溶质（从低分子量溶质到高分子量溶质）的清除率。这项研究将满足国家糖尿病、消化和肾脏疾病研究所 (NIDDK) 的需求，特别是其肾脏、泌尿和血液疾病部门的需求。 NIDDK 正在寻求“开发新的透析膜以缩短透析治疗的持续时间”。当商业化时，新膜将为透析患者提供更高的平均剂量，并提高他们的生活质量。